Search Results - "Maccubbin, D L"

Protective specific immunity induced by doxorubicin plus TNF‐α combination treatment of EL4 lymphoma–bearing C57BL/6 mice by Ehrke, M. Jane, Verstovšek, Srdan, Maccubbin, Darbie L., Ujházy, Peter, Zaleskis, Gintaras, Berleth, Erica, Mihich, Enrico

“…The therapeutic efficacy of a single (day 8), moderate dose (4 mg/kg, i.v.) of doxorubicin (DOX, Adriamycin) combined with recombinant human TNF‐α (3 different…”
Get full text

Thymic anti‐tumor effectors in mice cured of lymphoma by cyclophosphamide plus TNF‐α therapy: Phenotypic and functional characterization up to 20 months after initial tumor inoculation by Ehrke, M. Jane, Verstovsek, Srdan, Pocchiari, Susan K., Krawczyk, Christian M., Ujházy, Peter, Zaleskis, Gintaras, Maccubbin, Darbie L., Meer, Jane M., Mihich, Enrico

“…As reported previously, cyclophosphamide plus tumor necrosis factor‐α treatment of C57BL/6 mice bearing advanced EL4 lymphoma induced approx. 60% long‐term…”
Get full text

Adriamycin-induced modulation of host defenses in tumor-bearing mice by MACCUBBIN, D. L, WING, K. R, MACE, K. F, HO, R. L. X, EHRKE, M. J, MIHICH, E

“…Using the C57BL/6/EL4 tumor model, studies were carried out to demonstrate the feasibility of administering Adriamycin (ADM) in therapeutic doses and schedules…”
Get full text

Doxorubicin plus tumor necrosis factor α combination treatments in EL4-lymphoma-bearing C57BL/6 mice by EHRKE, M. J, VERSTOVSEK, S, UJHAZY, P, MEER, J. M, EPPOLITO, C, MACCUBBIN, D. L, MIHICH, E

“…The therapeutic efficacy of a total of 42 single-agent or combination protocols involving doxorubicin (Adriamycin, ADM) and tumor necrosis factor alpha…”
Get full text

MHC-restricted cytotoxic response of chicken T cells: expression, augmentation, and clonal characterization by Maccubbin, DL, Schierman, LW

“…Major histocompatibility complex (MHC)-restricted cytotoxicity of chicken lymphocytes was studied by using three reticuloendotheliosis virus (REV)-transformed…”
Get full text

Specific anti-EL4-lymphoma immunity in mice cured 2 years earlier with doxorubicin and interleukin-2 by EHRKE, M. J, VERSTOVSEK, S, ZALESKIS, G, HO, R. L. X, UJHAZY, P, MACCUBBIN, D. L, MIHICH, E

“…This laboratory has reported the conditions for an effective, non-toxic, chemoimmunotherapy utilizing doxorubicin in combination with prolonged administration…”
Get full text

Role of tumor necrosis factor in macrophage activation and tumoricidal activity by MACE, K. F, EHRKE, M. J, HORI, K, MACCUBBIN, D. L, MIHICH, E

“…Tumor necrosis factor (TNF)-sensitive (LM) and -insensitive (P815) target cell lines were used to examine the role of TNF in both the activation and lytic…”
Get full text

Polymyxin B-mediated lysis of tumor cells by Verstovsek, S, Maccubbin, D L, Ehrke, M J, Mihich, E

“…Polymyxin B (PmB) in the concentration range of 10-50 micrograms/ml is used routinely in immunological studies to neutralize low levels of contaminating…”
Get more information

Lipopolysaccharide and splenic tumoricidal macrophage activation by Verstovsek, S, Zaleskis, G, Maccubbin, D L, Mihich, E, Ehrke, M J

“…Splenic macrophage tumoricidal activity was examined and a splenic macrophage tumoricidal assay was established. Initially, mixtures of lipopolysaccharide…”
Get more information

Murine splenic macrophage tumoricidal activation by cytokines by Verstovsek, S, Eppolito, C, Ujhazy, P, Maccubbin, D L, Ehrke, M J, Mihich, E

“…Interleukin-2 (IL-2), IL-1 beta, interferon-gamma (IFN-gamma), and tumor necrosis factor-alpha (TNF-alpha), each alone and in all possible combinations, were…”
Get more information

Modification of host antitumor defense mechanisms in mice by progressively growing tumor by MACCUBBIN, D. L, MACE, K. F, EHRKE, M. J, MIHICH, E

“…The EL4 lymphoma in C57BL/6 mice was used as a model to examine the effect of progressive tumor growth on a variety of cell mediated cytolytic effector…”
Get full text

Immunological responses critical to the therapeutic effects of adriamycin plus interleukin 2 in C57BL/6 mice bearing syngeneic EL4 lymphoma by Ho, R L, Maccubbin, D L, Ujházy, P, Zaleskis, G, Eppolito, C, Mihich, E, Ehrke, M J

“…A safe and effective therapeutic combination of moderate doses of Adriamycin (doxorubicin, 4 mg/kg, IV, Days 1 and 8 or only Day 8) plus prolonged…”
Get more information

Indomethacin modulation of adriamycin-induced effects on multiple cytolytic effector functions by MACCUBBIN, D. L, COHEN, S. A, EHRKE, M. J

“…The anticancer agent, Adriamycin (ADM), in addition to being a potent cytotoxic drug has been shown to be an effective immunomodulator. This study was…”
Get full text

Cyclophosphamide plus tumor necrosis factor-alpha chemoimmunotherapy cured mice: life-long immunity and rejection of re-implanted primary lymphoma by Ehrke, M J, Verstovsek, S, Krawczyk, C M, Ujházy, P, Zaleskis, G, Maccubbin, D L, Mihich, E

“…Changes in functionally and phenotypically definable splenocyte subsets in aging mice which had been rendered tumor-free in early life by immunochemotherapy…”
Get more information

Comparison of adriamycin induced immunomodulation with that of the noncardiotoxic anthracycline 5-iminodaunorubicin by Maccubbin, D L, Whitman, J A, Taniguchi, N, Mace, K F, Ehrke, M J, Mihich, E

“…Adriamycin (ADM) has been shown to modulate a variety of host immune responses. Although the mechanism(s) for this activity is not known, it has been suggested…”
Get more information

Comparative effects of simvastatin and atorvastatin in hypercholesterolemic patients with characteristics of metabolic syndrome by Hunninghake, Donald B., Ballantyne, Christie M., Maccubbin, Darbie L., Shah, Arvind K., Gumbiner, Barry, Mitchel, Yale B.

“…Background: Hypercholesterolemic patients with metabolic syndrome (MS) are at high risk for coronary heart disease. The National Cholesterol Education Program…”
Get full text

Effects of simvastatin on C-reactive protein in mixed hyperlipidemic and hypertriglyceridemic patients by Bays, Harold E, Stein, Evan A, Shah, Arvind K, Maccubbin, Darbie L, Mitchel, Yale B, Mercuri, Michele

“…This study examined the effects of simvastatin on C-reactive protein (CRP) and other inflammatory markers in study subjects with significant elevations in…”
Get full text

Effects of simvastatin on the lipid profile and attainment of low-density lipoprotein cholesterol goals when added to thiazolidinedione therapy in patients with type 2 diabetes mellitus: A multicenter, randomized, double-blind, placebo-controlled trial by Lewin, Andrew J., Kipnes, Mark S., Meneghini, Luigi F., Plotkin, Diane J., Perevozskaya, Inna T., Shah, Sukrut, Maccubbin, Darbie L., Mitchel, Yale B., Tobert, Jonathan A.

“…Background: Coronary heart disease is the major cause of mortality in individuals with diabetes mellitus (DM). Given the increasingly aggressive low-density…”
Get full text

MHC-restricted cytotoxic response of chicken T cells: Expression, augmentation, and cloned characterization by Maccubbin, D L, Schierman, L W

“…Major histocompatibility complex (MHC)-restricted cytotoxicity of chicken lymphocytes was studied by using three reticuloendotheliosis virus (REV)-transformed…”
Get full text

MHC-restricted cytotoxic response of chicken T cells: expressionm augmentation, and clonal characterization by MACCUBBIN, D. L, SCHIERMAN, L. W

Get full text